27 July 2022 - The EMA’s Emergency Task Force has started a review of data on the use of sabizabulin for treating COVID-19.

The review will look at all available data, including data from a study involving hospitalised patients with moderate-to-severe COVID-19 who are at high risk of acute respiratory distress syndrome and death. The results of this study indicate that sabizabulin treatment could reduce the number of deaths in these patients compared with placebo.

Read EMA press release